Biocytogen
Dr. Zhihong Li has been the deputy general manager of the Company since December 2020, and their chief regulatory and strategy officer of the Eucure (Beijing) since March 2019. Dr. Li has clinical development and review experience in several therapeutics areas including oncology. He worked at Pfizer Inc., and was as staff fellow at Food and Drug Administration of the United States from May 2009 to December 2007. Dr. Li obtained a bachelor’s degree and a master’s degree in pharmacy in July 1992 and in June 1995 respectively from Beijing Medical University in the PRC. In March 2007, he obtained a doctor of philosophy degree from the University of Minnesota in the United States.
This person is not in any offices
Biocytogen
2 followers
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for antibody drug discovery, Biocytogen offers animal model generation, antibody fully human-mouse (RenMab mouse), therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO, and regulatory affairs support.